Form 4: Vera Therapeutics COO Sells Shares for Tax Obligations

Vera Therapeutics' Chief Operating Officer, David Lee Johnson, sold 2,579 shares of Class A Common Stock to cover tax withholding obligations related to RSU vesting.

Summary

• David Lee Johnson, Chief Operating Officer of Vera Therapeutics, Inc. (VERA), reported a sale of Class A Common Stock.
• A total of 2,579 shares were sold at a weighted-average price of $41.9839 per share.
• The sales occurred over a two-business-day period, beginning on February 23, 2026, and ending on February 24, 2026.
• The transaction was a 'sell-to-cover' sale, mandated by the Issuer's equity incentive plans to satisfy tax withholding obligations incurred upon the vesting of restricted stock units (RSUs).
• This transaction does not represent a discretionary trade by the reporting person.
• Following the transaction, David Lee Johnson directly beneficially owns 45,727 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine, non-discretionary sale to cover tax obligations associated with RSU vesting, rather than a discretionary trade reflecting management's sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are a standard and common practice in the industry for executives to meet tax obligations upon the vesting of equity awards like Restricted Stock Units. This type of transaction is generally not indicative of management's discretionary view on the company's future prospects, unlike open market sales.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary 'sell-to-cover' transaction by an executive to satisfy tax obligations from RSU vesting. Such transactions are common and do not typically signal a change in the company's fundamentals or management's outlook, thus providing no new information to alter an existing investment thesis. A 'hold' recommendation is appropriate as this filing alone does not warrant a change in investment strategy.

Keywords

Vera Therapeutics, VERA, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Sell-to-Cover, David Lee Johnson, Chief Operating Officer